Clinical Trial Update: Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

An early-phase exploratory clinical study evaluating the safety and potential efficacy of an anti-CD19/BCMA U CAR-T cell therapy for relapsed/refractory autoimm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antineutrophil Cytoplasmic Antibody-associated Vasculitis
• Rheumatoid Arthritis
• Sjögren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• Anti-CD19/BCMA U CAR-T cell

Snippet

Sponsor: Changhai Hospital | Conditions: Autoimmune Diseases, Systemic Lupus Erythematosus | EARLY_Phase 1 | Status: RECRUITING